Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StrataXRT is a silicone-based, film-forming topical gel developed by Stratpharma AG for the prevention and treatment of radiation-induced dermatitis. It is a non-sterile, semi-occlusive wound dressing that forms a thin, flexible, and waterproof protective film when applied to the skin. This film adheres to the skin's contours, providing a physical barrier that protects the affected area from external factors while maintaining a moist environment to facilitate healing and reduce symptoms such as erythema, pain, and itching. Unlike some other topical agents, it does not have a bolus effect, making it suitable for use during radiation therapy sessions. It has been evaluated in clinical trials sponsored by the OHSU Knight Cancer Institute for patients with breast and head and neck cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on StrataXRT.